Novartis AG

Suisse


Commandez votre montre hebdomadaire Novartis AG
Quantité totale PI 10 494
Quantité totale incluant filiales 19 292 (+ 8 897 pour les filiales)
Rang # Quantité totale PI 94
Note d'activité PI 4,2/5.0    4 186
Rang # Activité PI 137
Activité incl filiales 4,3/5.0    7 646
Symbole boursier
ISIN CH0012005267
Capitalisation 178.7B  (CHF)
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

1 940 1 137
556 826
3 241 1 958
836
 
Dernier brevet 2026 - Binding molecules against bcma a...
Premier brevet 1977 - Organic compounds
Dernière marque 2026 - FALCON
Première marque 1942 - METHERGINE

Filiales

119 subsidiaries with IP (6025 patents, 2872 trademarks)

89 subsidiaries without IP

 S'inscrire grtuitement pour accéder à la liste des filiales

Industrie (Classification de Nice)

Derniers inventions, produits et services

2026 P/S Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal prep...
P/S Non-medicated toilet preparations and skin care products; cosmetic and beauty preparations; cosme...
P/S Pharmaceutical preparations and gene therapy products in the nature of injectable biological prep...
2025 P/S Pharmaceutical preparations.
P/S Analgesics; Anti-inflammatories; Topical analgesic creams; Analgesic balm; Pharmaceutical prepara...
P/S Analgesics; Anti-inflammatories; Pharmaceutical preparations for the treatment of pain and pain r...
P/S Non-medicated toilet preparations and skin care products, cosmetic and beauty preparations, cosme...
P/S Downloadable mobile application for patient education and training in the use and administration ...
P/S Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à sa...
P/S Foot deodorant spray; Non-medicated foot lotions; Antiperspirants; Cosmetic preparations
P/S Pharmaceutical preparations. Medical apparatus and instruments.
Invention Methods of using factor b inhibitors. Described herein are methods of treating paroxysmal noctur...
Invention Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor. The invention pr...
Invention Use of labeled inhibitors of prostate specific membrane antigen (psma), as agents for the treatme...
Invention Prostate specific membrane antigen (psma) ligands and uses thereof. The present disclosure relat...
Invention Identifying patient response to s1p receptor modulator administration. The invention provides a ...
Invention Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor. Th...
Invention Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d). The prese...
Invention Synthesis of a precursor of radiopharmaceutical products. The present disclosure is directed to a...
Invention Aminoisoquinoline compounds and methods of using thereof. The present invention relates to a comp...
Invention Methods of treating sjogren's syndrome using a bruton's tyrosine kinase inhibitor. The present d...
Invention Double stranded rnai agents, compositions and methods of use. Disclosed are, inter alia, double ...
Invention Double stranded rnai agents, compositions and methods of use. Disclosed are, inter alia, double s...
Invention Double stranded rnai agents, compositions and methods of use. Disclosed are, inter alia, therapeu...
Invention Chimeric antigen receptors and uses thereof. The invention provides immune effector cells (for e...
Invention 7h-pyrrolo[2,3-d]pyrimidine derivatives as cyclin-dependent kinase inhibitors useful for the trea...
Invention Cyclin-dependent kinase inhibitors. The invention relates to compounds which inhibit Cyclin-Depe...
Invention Angiopoietin-like protein 4 antibody-based treatment. Methods, kits, and compositions are provide...
Invention Treatment of systemic sclerosis using anti-baff-r antibodies. The disclosure relates to methods, ...
Invention Stable, concentrated radiopharmaceutical composition. The present disclosure relates to radionuc...
Invention Treatment of cancer using a cd33 chimeric antigen receptor. The invention provides compositions ...
Invention Lipid-modified nucleic acid compounds and methods. Disclosed herein, inter alia, are lipid-modif...
Invention Dosing regimens for n-(3-cyano-5-(cyclohexylmethyl)-6,6-dimethyl-4,5,6,7-tetrahydrothieno[3,2-c]p...
Invention Antiviral pyrazolopyridinone compounds. The invention provides compounds of Formula (I) The in...
Invention Fgf21 mimetic antibodies and uses thereof. The present disclosure relates to monoclonal antibodi...
Invention Molecular glue degrader compounds and uses thereof. Described herein are molecular glue degrader ...
Invention Pharmaceutical formulations of an androgen receptor-targeting protein degrader. The present discl...
Invention Pharmaceutical formulations of an androgen receptor-targeting protein degrader. The present disc...
Invention Her2 targeting cyclic peptides and conjugates thereof. Described herein are cyclic peptides targ...
Invention Her2 targeting cyclic peptides and conjugates thereof. Described herein are cyclic peptides targe...
Invention Novel pharmaceutical composition. The invention pertains to dispersible tablets comprising as ac...
Invention Binding molecules against bcma and uses thereofprivate view. The present disclosure provides BCM...
Invention Antibody molecules to lag-3 and uses thereof. Antibody molecules that specifically bind to LAG-3...
Invention Immune effector cell therapies with enhanced efficacy. The present invention relates generally t...
Invention Cell-based assay for measuring drug product potency. The invention relates to the an in vitro qu...
2024 Invention Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-...
Invention Shp inhibitor compositions and uses for chimeric antigen receptor therapy. Compositions and meth...
Invention Nucleic acid ligation method. The present disclosure relates to biocatalytic ligation methods for...
2023 Invention Nucleic acid ligation method. The present disclosure relates to biocatalytic ligation methods fo...
Invention Crystalline forms of an akric3 dependent kars inhibitor. This application relates to crystalline...
Invention Pharmaceutical compositions of tricyclic akr1c3 dependent kars inhibitor and methods for making s...
Invention Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention. The present ...
Invention (s)-engineered oxynitrilase polypeptides and uses thereof. The present disclosure relates to a p...
Invention Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof. Anti-EphA2 antibody-...
Invention Antibody-drug conjugates of antineoplastic compounds and methods of use thereof. Antibody-drug c...
Invention Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof. Anti-Met antibody-drug...
Invention Novel recombinant aav vp2 fusion polypeptides. This disclosure relates to adeno-associated virus...
Invention Dosage regimens for anti-cd19 agents and uses thereof. The present disclosure relates to dosage ...
2022 Invention Combination therapy of radionuclide complex. The present disclosure is directed to a method of t...
Invention Surfactant stabilizers. The present invention is directed to stabilized protein-containing formu...